ONVO オーガノボ・ホールディングス
- 0.360
- -0.012-3.28%
- 0.360
- 0.0000.00%
オーガノボ・ホールディングスのニュース一覧
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
オーガノボ・ホールディングス | 10-Q：Q2 2025 四半期報告書
Organovo Holdings Files for Offering of Stock and Warrants
オルガノボ ホールディングス | 10-Q：Q1 2025 四半期報告書
オルガノボ ホールディングス | 10-K/A：有価証券報告書(訂正)
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
オルガノボ ホールディングス | 10-K：FY 2024 年度報告書
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy With Tofacitinib for Inflammatory Bowel Disease
Organovo Granted U.S. Patent #11982668: Use Of Engineered Renal Tissues In Assays
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Reported Earlier, Organovo Prices $5.25M Public Offering Of 6,562,500 Common Shares And Common Warrants At A Combined Price Of $0.80
Organovo Holdings' Offering of 6.6 Million Shares and Warrants Prices at 80 Cents a Share and Warrant
Organovo Holdings Announces Pricing of $5.25M Public Offering
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
INVO, EZGO and WISA Among Pre-market Losers
肝脂肪显著降低！Organovo Holdings(ONVO.US)MASH疗法积极试验结果公布
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
データなし